Exact Mass: 1074.4573
Exact Mass Matches: 1074.4573
Found 16 metabolites which its exact mass value is equals to given mass value 1074.4573
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mpomeovt
5-amino-2-({1-[19-(butan-2-yl)-16-(2-carbamoylethyl)-13-(carbamoylmethyl)-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidin-2-yl}formamido)-N-(carbamoylmethyl)pentanamide
Pyoverdin G4R
3-[(4-Amino-1-{[2-carboxy-2-hydroxy-1-(6-{[({2-hydroxy-1-[(1-hydroxy-2-oxopiperidin-3-yl)-C-hydroxycarbonimidoyl]ethyl}-C-hydroxycarbonimidoyl)methyl]-C-hydroxycarbonimidoyl}-1,4,5,6-tetrahydropyrimidin-2-yl)ethyl]-C-hydroxycarbonimidoyl}butyl)-C-hydroxycarbonimidoyl]-3-[({8,9-dihydroxy-5-[3-(C-hydroxycarbonimidoyl)propanamido]-1H,2H,3H,4H,4ah-pyrimido[1,2-a]quinolin-1-yl}(hydroxy)methylidene)amino]propanoate
URANTIDE
3-Amino-3-{[10-(3-aminopropyl)-16-benzyl-4-[(1-carboxy-2-methylpropyl)-C-hydroxycarbonimidoyl]-6,9,12,15,18-pentahydroxy-7-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-20,20-dimethyl-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}propanoate
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin trifluoroacetate salt
N-[5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[13-(2-amino-2-oxoethyl)-16-(3-amino-3-oxopropyl)-19-butan-2-yl-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
4-[[5-amino-1-[[2-carboxy-2-hydroxy-1-[6-[[2-[[3-hydroxy-1-[(1-hydroxy-2-oxopiperidin-3-yl)amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]carbamoyl]-1,4,5,6-tetrahydropyrimidin-2-yl]ethyl]amino]-1-oxopentan-2-yl]amino]-3-[[5-[(4-amino-4-oxobutanoyl)amino]-8,9-dihydroxy-2,3,4,4a-tetrahydro-1H-pyrimido[1,2-a]quinoline-1-carbonyl]amino]-4-oxobutanoic acid
4-[[5-amino-1-[[2-carboxy-2-hydroxy-1-[6-[[2-[[3-hydroxy-1-[(1-hydroxy-2-oxopiperidin-3-yl)amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]carbamoyl]-1,4,5,6-tetrahydropyrimidin-2-yl]ethyl]amino]-1-oxopentan-2-yl]amino]-3-[[5-[(4-amino-4-oxobutanoyl)amino]-8,9-dihydroxy-2,3,4,4a-tetrahydro-1H-pyrimido[1,2-a]quinoline-1-carbonyl]amino]-4-oxobutanoic acid
D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents
BIM-26226
BIM-26226
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer[1][2].
16'-[(3,4-dihydroxy-5-{[5-hydroxy-6-(hydroxymethyl)-3,4-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl)oxy]-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one
16'-[(3,4-dihydroxy-5-{[5-hydroxy-6-(hydroxymethyl)-3,4-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl)oxy]-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one
(2s,3s,6r,8s)-8-[(2s,3s,6r,9s)-3-{[(2r)-2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl]-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
(2s,3s,6r,8s)-8-[(2s,3s,6r,9s)-3-{[(2r)-2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl]-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
(2e,5r,8s,11r,15s,18s,19s,22r)-2-ethylidene-3,6,9,13,16,20,25-heptahydroxy-8-[2-(4-hydroxyphenyl)ethyl]-15-(1h-indol-3-ylmethyl)-18-[(1e,3e,5s,6s)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-5,19-dimethyl-1,4,7,10,14,17,21-heptaazacyclopentacosa-1(25),3,6,9,13,16,20-heptaene-11,22-dicarboxylic acid
(2e,5r,8s,11r,15s,18s,19s,22r)-2-ethylidene-3,6,9,13,16,20,25-heptahydroxy-8-[2-(4-hydroxyphenyl)ethyl]-15-(1h-indol-3-ylmethyl)-18-[(1e,3e,5s,6s)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-5,19-dimethyl-1,4,7,10,14,17,21-heptaazacyclopentacosa-1(25),3,6,9,13,16,20-heptaene-11,22-dicarboxylic acid
8-(3-{[2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl)-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl 3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
8-(3-{[2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl)-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl 3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
(1'r,2s,2'r,4's,7's,8'r,9's,12'r,13'r,16's)-16'-{[(2r,3r,4r,5r,6r)-3,4-dihydroxy-5-{[(2s,3r,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl]oxy}-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one
(1'r,2s,2'r,4's,7's,8'r,9's,12'r,13'r,16's)-16'-{[(2r,3r,4r,5r,6r)-3,4-dihydroxy-5-{[(2s,3r,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl]oxy}-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one